Immobilized human IL-17A at 0.5 μg/ml (50 μL/well) can bind to Secukinumab with a linear range of 1.221 ng/ml-5 μg/ml.
Product Details
Product Details
Product Specification
Host | Human |
Antigen | IL-17A |
Synonyms | Interleukin-17A, Cytotoxic T-lymphocyte-associated antigen 8 (CTLA-8), CTLA8, IL17 |
Accession | Q16552 |
Clone Number | S-SC013 |
Antibody Type | Recombinant mAb |
Isotype | IgG1,k |
Application | Blocking of IL-17A signaling Functional assays |
Purification | Protein A |
Concentration | 2 mg/ml |
Endotoxin | <1EU/mg |
Conjugation | Unconjugated |
Physical Appearance | Liquid |
Storage Buffer | PBS pH7.4, containing no preservative |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
application | dilution | species |
ELISA | 1.221-5000 ng/ml |
Background
Secukinumab is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A.
Picture
Picture
ELISA
